8-K - Hoth Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Hoth Therapeutics closed a $2.0 million registered direct offering of 2.86 million shares at $0.70 per share with concurrent unregistered warrants, intending to use proceeds for working capital.

Key Takeaways

1Company sold 2,857,144 shares of common stock at a price of $0.70 per share for gross proceeds of approximately $2.0 million.

2Investors received unregistered warrants to purchase 2,857,144 shares at an exercise price of $0.85, exercisable in six months.

3H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee and warrants to purchase 142,857 shares.

4Net proceeds are designated for working capital and general corporate purposes.

5The Company suspended its existing At-the-Market (ATM) sales agreement prospectus effective April 1, 2026.

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement.** ** ** On April 1, 2026, Hoth Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the

Material Agreement

$2.0MH.C. Wainwright & Co.

Source Document

3.02

Unregistered Sales of Equity Securities.** Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference

Securities Issuance

8.01

** **Other Events.** ** ** Press Releases On April 1, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press relea

Other Event

9.01

Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 4.1 | | Form of Warrant | | 4.2 | | Form of Placement Agent W

Exhibits Only

Source Document

Transaction Details

Material Agreement

Agreement: Securities Purchase Agreement
Parties: Hoth Therapeutics, Inc., Certain institutional investors

•Sale of 2,857,144 shares of Common Stock at $0.70 per share.
•Concurrent private placement of unregistered warrants to purchase 2,857,144 shares at $0.85 exercise price.
•Warrants exercisable six months from issuance for a period of five years.
•Warrants contain a beneficial ownership limitation of 4.99% (adjustable to 9.99%).
•Closing occurred on April 2, 2026.
•Gross proceeds of approximately $2 million.
•Placement Agent: H.C. Wainwright & Co., LLC.
•Placement Agent compensation: 7.0% cash fee, 1.0% management fee, and warrants to purchase 142,857 shares at $0.875.
•Use of proceeds: Working capital and general corporate purposes.

Exhibits (7)

10.1

FORM OF SECURITIES PURCHASE AGREEMENT

4.1

FORM OF WARRANT

4.2

FORM OF PLACEMENT AGENT WARRANT

5.1

OPINION OF SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

8-K

CURRENT REPORT

99.1

PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED APRIL 1, 2026

99.2

PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED APRIL 2, 2026